Northern Trust Corp grew its holdings in shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free R...
HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of DiaMedica Therapeut...
Key Insights DiaMedica Therapeutics' significant insider ownership suggests inherent interests in co...
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma...
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma...